Weaver Consulting Group’s Fortress Biotech FBIO Stock Holding History

Weaver Consulting Group’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.7K	Sell	10,367 -1,000	-9%	-$2.58K	0.01%	297
2026 Q1	$31.7K	Sell	11,367 -8,165	-42%	-$27.7K	0.01%	275
2025 Q4	$71.5K	Sell	19,532 -1,080	-5%	-$3.08K	0.02%	268
2025 Q3	$76.2K	Sell	20,612 -24,305	-54%	-$61.5K	0.02%	263
2025 Q2	$83.5K	Sell	44,917 -1,500	-3%	-$2.6K	0.02%	243
2025 Q1	$72.4K	Buy	46,417 +23,419	+102%	+$41.3K	0.02%	220
2024 Q4	$46.6K	Buy	22,998 +5,700	+33%	+$10.3K	0.01%	217
2024 Q3	$25K	Buy	17,298 +5,895	+52%	+$11.2K	0.01%	222
2024 Q2	$19.5K	Buy	+11,403	New	+$20.7K	0.01%	203

Other funds holding FBIO

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Weaver Consulting Group's FBIO Position: Q2 2026 in Review

Weaver Consulting Group reduced its Fortress Biotech (FBIO) stake by 8.8% in Q2 2026, selling an estimated $2.58K and leaving 10,367 shares worth $31.7K. The position accounts for 0.01% of the portfolio, ranked #297.

Weaver Consulting Group first reported a position in FBIO in Q2 2024 and has held it in 9 quarters since. The position peaked at $83.5K in Q2 2025. 55 funds tracked by Wall St. Rank hold FBIO as of Q2 2026.

Weaver Consulting Group held 10,367 shares of Fortress Biotech worth $31.7K as of Q2 2026.
Weaver Consulting Group sold 1,000 Fortress Biotech shares in Q2 2026, an estimated $2.58K.
Fortress Biotech made up 0.01% of Weaver Consulting Group's portfolio in Q2 2026, its #297 holding.
Weaver Consulting Group first reported a position in Fortress Biotech in Q2 2024 and has held it in 9 quarters since.
Weaver Consulting Group's Fortress Biotech position peaked at $83.5K in Q2 2025.
55 funds tracked by Wall St. Rank held Fortress Biotech as of Q2 2026.

Based on Weaver Consulting Group's 13F filing for Q2 2026, filed 29 Jul 2026.